MarketCap
Facebook
X
Telegram
Protalix BioTherapeutics Net Income | PLX
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Protalix BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.6 M | 2.93 M | 8.31 M | -14.9 M | -27.6 M | -6.52 M | -18.3 M | -26.5 M | -85.3 M | -29.4 M | 58 M | -29.9 M | -27.8 M | -11.6 M | -36.5 M | -29 M | -31.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58 M | -85.3 M | -18.4 M |
Quarterly Net Income Protalix BioTherapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 164 K | 18.3 M | - | 2.36 M | 164 K | -3.62 M | - | 3.24 M | -2.2 M | -4.6 M | - | -1.85 M | 19.3 M | -3.13 M | - | -3.57 M | -5.33 M | -2.29 M | - | -4.2 M | -11.2 M | -5.48 M | - | -4.44 M | -4.15 M | 1.67 M | 291 K | -3.56 M | -7.74 M | -7.26 M | -5.43 M | -5.32 M | -8.46 M | -7.24 M | - | -11.4 M | 450 K | -59.1 M | - | -7.29 M | -10.9 M | -8.6 M | - | -3.82 M | -5.07 M | -5.97 M | - | -8.01 M | -6.12 M | -7.34 M | - | -5.75 M | -6.84 M | -4.32 M | - | -5.48 M | 9.64 M | -5.9 M | - | -8.88 M | -13.7 M | -5.05 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 19.3 M | -59.1 M | -4.8 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Celsion Corporation
CLSN
|
14.5 M | - | -6.63 % | $ 13.9 M |  USA |
 |
FSD Pharma
HUGE
|
-27 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Qilian International Holding Group Limited
QLI
|
-19.9 M | - | -6.08 % | $ 184 M |  China |
 |
Happiness Biotech Group Limited
HAPP
|
-7.89 M | - | 1.35 % | $ 17.8 M | China |
 |
Synthetic Biologics
SYN
|
-23.7 M | - | 1.32 % | $ 16.2 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
27.3 M | - | - | $ 2.02 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-69.9 M | $ 1.19 | 5.31 % | $ 14.5 M | USA |
 |
Burford Capital Limited
BUR
|
62.6 M | $ 4.37 | 0.23 % | $ 958 M |  Britain |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | China |
 |
BeyondSpring
BYSI
|
-1.01 M | $ 0.84 | 34.27 % | $ 34.5 M | USA |
 |
Corner Growth Acquisition Corp.
COOL
|
-322 K | - | -0.89 % | $ 114 M | USA |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17 M | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-15.6 M | $ 2.98 | 4.93 % | $ 568 M | USA |
 |
Compugen Ltd.
CGEN
|
35.3 M | $ 2.41 | 4.17 % | $ 225 M |  Israel |
 |
CureVac N.V.
CVAC
|
162 M | - | - | $ 867 M |  Germany |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
-106 M | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-40 M | - | 0.74 % | $ 768 M | Israel |
 |
Abcam plc
ABCM
|
-8.5 M | - | - | $ 4.9 B | Britain |
 |
Завод ДИОД
DIOD
|
37.2 M | - | - | - |  Russia |
|
Galera Therapeutics
GRTX
|
149 M | - | -32.59 % | $ 7.61 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.38 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Hepion Pharmaceuticals
HEPA
|
-8.28 M | - | -18.79 % | $ 39.3 K | USA |
 |
ARCA biopharma
ABIO
|
-105 M | - | 1052.0 % | $ 415 M | USA |
 |
MorphoSys AG
MOR
|
-190 M | - | 2.43 % | $ 254 M | Germany |
|
Champions Oncology
CSBR
|
-1.18 M | $ 5.1 | 2.63 % | $ 70.5 M | USA |
 |
Affimed N.V.
AFMD
|
-106 M | - | -34.95 % | $ 21.5 M | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
-102 M | - | -1.58 % | $ 28.1 M | China |
 |
Celyad Oncology SA
CYAD
|
-40.9 M | - | - | $ 12.5 M |  Belgium |
 |
Adial Pharmaceuticals
ADIL
|
-7.98 M | $ 3.98 | 1.86 % | $ 2.66 M | USA |
 |
Generation Bio Co.
GBIO
|
-132 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
AnaptysBio
ANAB
|
-13.2 M | $ 58.47 | 4.37 % | $ 1.68 B | USA |
 |
Anika Therapeutics
ANIK
|
-10.9 M | $ 21.5 | 1.56 % | $ 308 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3 M | - | -4.36 % | $ 27 M | USA |
 |
Gracell Biotechnologies
GRCL
|
-608 M | - | - | $ 3.37 B | China |
 |
Aurinia Pharmaceuticals
AUPH
|
287 M | $ 15.47 | 1.91 % | $ 2.08 B | Canada |
 |
GlycoMimetics
GLYC
|
154 K | - | 9357.83 % | $ 1.01 B | USA |
 |
Aeterna Zentaris
AEZS
|
-10.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AVROBIO
AVRO
|
-74.2 B | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bicycle Therapeutics plc
BCYC
|
-219 M | $ 3.9 | 0.24 % | $ 270 M | Britain |
 |
Beam Therapeutics
BEAM
|
-80 M | $ 26.75 | 0.91 % | $ 2.65 B | USA |
 |
AIkido Pharma
AIKI
|
-22.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
349 M | $ 67.36 | 0.99 % | $ 12.9 B | USA |
 |
Aptose Biosciences
APTO
|
-25.5 M | - | -45.71 % | $ 1.2 M | Canada |